Deborah Ann Knee

US Patent:

8173128, May 8, 2012

Filed:

Dec 1, 2006

Appl. No.:

11/607208

Inventors:

Marc Nasoff - San Diego CA, US
Quinn L. Deveraux - San Diego CA, US
Deborah A. Knee - Del Mar CA, US
Garrett M. Hampton - San Diego CA, US
Klaus Wagner - San Diego CA, US

Assignee:

IRM LLC - Hamilton

International Classification:

A61K 39/395
A61K 38/16

US Classification:

4241381, 4241331, 4241351, 514 189, 514 193

Abstract:

Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.

US Patent:

20050079172, Apr 14, 2005

Filed:

Nov 25, 2003

Appl. No.:

10/723383

Inventors:

Marc Nasoff - San Diego CA, US
Quinn Deveraux - San Diego CA, US
Deborah Knee - Del Mar CA, US
Garret Hampton - San Diego CA, US
Klaus Wagner - San Diego CA, US

Assignee:

IRM LLC, a Delaware Limited Liability Company - Hamilton

International Classification:

A61K039/395

US Classification:

424141100, 424143100

Abstract:

Anti-DR4 or Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.

US Patent:

20220348651, Nov 3, 2022

Filed:

Sep 17, 2020

Appl. No.:

17/642763

Inventors:

- Basel, CH
Mirek Dostalek - Binningen, CH
Christoph Erkel - Puchheim, DE
Javier Estrada Diez - Somerville MA, US
Anna Galkin - Encinitas CA, US
Scott Martin Glaser - San Diego CA, US
Klaus Felix Hartlepp - München, DE
Yong Jia - San Diego CA, US
Deborah A. Knee - Del Mar CA, US
Alexandra Kraus - München, DE
Christian Cho-Hua Lee - San Diego CA, US
Luigi Manenti - Livingston NJ, US
Sarah Michelle Rue - San Diego CA, US
Jian Shi - San Diego CA, US
Xenia Karola Wezler - München, DE
Gabrielle Wong - Cambridge MA, US

International Classification:

C07K 16/28
A61P 35/00
C07K 16/30

Abstract:

Provided herein are methods of treating cancer using an antibody or antigen-binding fragments thereof that specifically bind to human ENTPD2 protein, and compositions comprising these antibodies or antigen-binding fragments for use in the treatment of cancer. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

US Patent:

20220340685, Oct 27, 2022

Filed:

Sep 17, 2020

Appl. No.:

17/642766

Inventors:

- Basel, CH
Mirek Dostalek - Binningen, CH
Christoph Erkel - Puchheim, DE
Javier Estrada Diez - Somerville MA, US
Anna Galkin - Encinitas CA, US
Scott Martin Glaser - San Diego CA, US
Klaus Felix Hartlepp - München, DE
Yong Jia - San Diego CA, US
Deborah A. Knee - Del Mar CA, US
Alexandra Kraus - München, DE
Christian Cho-Hua Lee - San Diego CA, US
Luigi Manenti - Livingston NJ, US
Sarah Michelle Rue - San Diego CA, US
Jian Shi - San Diego CA, US
Xenia Karola Wezler - München, DE
Gabrielle Wong - Cambridge MA, US

International Classification:

C07K 16/40
C07K 16/28
C07K 16/22
A61P 35/00

Abstract:

Provided herein are combinations comprising an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to ENTPD2 (e.g., human ENTPD2 protein), and an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to CD73 (e.g., human CD73 protein), and methods of using these combinations.

US Patent:

20210015860, Jan 21, 2021

Filed:

Apr 9, 2020

Appl. No.:

16/845030

Inventors:

- Basel, CH
Daniela CIPOLLETTA - Arlington MA, US
Glenn DRANOFF - Lexington MA, US
Deborah A. KNEE - Del Mar CA, US
Fei WANG - San Diego CA, US

International Classification:

A61K 35/17
C07K 16/32
A61P 35/00

Abstract:

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors; as well as pharmaceutical compositions that comprise such molecules and methods of use thereof.

US Patent:

20170306037, Oct 26, 2017

Filed:

Oct 8, 2015

Appl. No.:

15/517867

Inventors:

- Basel, CH
Daniela CIPOLLETTA - Arlington MA, US
Glenn DRANOFF - Lexington MA, US
Deborah A. KNEE - Del Mar CA, US
Fei WANG - San Diego CA, US

International Classification:

C07K 16/28
A61K 39/00
A61K 39/00
A61K 39/00

Abstract:

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors; as well as pharmaceutical compositions that comprise such molecules and methods of use thereof.

US Patent:

20170306038, Oct 26, 2017

Filed:

Oct 8, 2015

Appl. No.:

15/517872

Inventors:

Jennifer BROGDON - Sudbury MA, US
Daniela CIPOLLETTA - Arlington MA, US
Glenn DRANOFF - Lexington MA, US
Deborah A. KNEE - Del Mar CA, US
Fei WANG - San Diego CA, US

International Classification:

C07K 16/28
C07K 16/28
A61K 45/06
A61K 39/00
A61K 39/00

Abstract:

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18), and compositions comprising one or more additional therapeutic agents. Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers. Also provided are methods of use of combinations that find use in treatment or prevention of cancerous or infectious conditions and disorders.